Tumor-induced osteomalacia caused by fibroblast growth factor 23 excess : Delayed diagnosis resulting from overlooked hypophosphatemia-A case report.

S. Aksun N. Basmaci M. Ayvaz D. P. Baran K. Kosemehmetoglu Yahya Eryilmaz E. Ergun A. Gürlek

Sep 2026 · Wiener Klinische Wochenschrift · 0 citations · 29 references

Medicine

TL;DR

A 39-year-old man with a 3-year history of progressive musculoskeletal pain is reported, in whom unrecognized hypophosphatemia led to misdiagnoses, including osteoporosis and inflammatory musculoskeletal disorders, and consequently, to inappropriate management.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Oct 2026

Tumor induced osteomalacia: a rare case report

Tumor-induced osteomalacia is a rare paraneoplastic syndrome caused by excessive fibroblast growth factor 23 (FGF23) secretion from phosphaturic mesenchymal tumors, leading to hypophosphatemia and osteomalacia. We present a 36-year-old female with progressive bilateral hip pain and pathological femoral neck fractures w...

Sharvari P. Varute, S. Patil, G. Pundkare · International Journal of Res... · 0 citations

Open access Oct 2026

Unmasking tumor-induced osteomalacia: A diagnostic odyssey from ankylosing spondylitis to fibroblast growth factor 23-mediated hypophosphatemia

Unexplained chronic musculoskeletal pain with insufficiency fractures necessitates early serum phosphate testing when calcium panel is normal, and tumor-induced osteomalacia remains a clinical and biochemical diagnosis even when culprit tumors evade initial functional imaging.

Rakesh Barshan Chaki, S. Jahan, S. Monisha et al. · Journal of Association of Cl... · 0 citations

Case report Oct 2026

Tumor-induced osteomalacia caused by a mandibular phosphaturic mesenchymal tumor misdiagnosed as giant cell reparative granuloma: case report.

Tumor-induced osteomalacia (TIO) is a rare syndrome caused by FGF23-secreting phosphaturic mesenchymal tumors (PMTs). Clinicians frequently misdiagnose mandibular PMTs due to their histological mimicry of giant cell lesions. We report a 16-year-old female with mandibular PMT-induced TIO who endured a 5-year diagnostic...

Lan-Lan Zhang, Sheng-Jie Shao, Ming-Li Liu et al. · Journal of Stomatology Oral... · 0 citations

2026

A case report of phosphaturic mesenchymal tumor-induced osteomalacia

Objective: presenting a case of phosphaturic mesenchymal tumor-induced osteomalacia (TIO). Case presentation: A 50-year-old woman arrived with severe widespread muscle weakness, weight loss, wheelchair reliance, gradual functional deterioration, and several spontaneous fractures involving both hips and the right arm....

Lina Hijazi, Rahf Aman, Rahaf Almoallim et al. · International Journal of Med... · 0 citations

Review Open access Sep 2026

Burosumab-responsive micro tumor-induced osteomalacia caused by a 6-mm phosphaturic mesenchymal tumor of the femoral head: a case report with review of literature on small (≤10 mm) FGF23-producing tumors.

A woman in her thirties presented with progressive bone pain, muscle weakness, recurrent stress fractures, and delayed fracture healing. Laboratory investigations demonstrated hypophosphatemia, renal phosphate wasting, elevated fibroblast growth factor 23 (FGF23), and inappropriately low 1,25-dihydroxyvitamin D, leadin...

N. Horiguchi, Kenichiro Okuno, Mari Arai-Uehara et al. · Endocrine journal · 0 citations

Open access Sep 2026

Tumor-Induced Osteomalacia in a Patient with Metastatic Prostate Cancer Presenting with Refractory Hypophosphatemia

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by fibroblast growth factor 23 (FGF23) overproduction, which leads to renal phosphate wasting and hypophosphatemia. Herein, we present the case of an 81-year-old man with metastatic prostate adenocarcinoma who presented with fatigue, diffuse bone...

Aparajita Roy, K. Mullins, A. Kyriakou et al. · The Eurasia Proceedings of H... · 0 citations